Coherus Biosciences is a biotechnology company in California that focuses on developing, manufacturing and commercializing biologic therapeutics or biosimilars for oncology and inflammatory diseases. Founded 2010 in Redwood City, California, United States by Stephen C. Glover, the company focuses on process science, analytical characterization, protein production, and clinical-regulatory development of biosimilars. Biosimilars are safe, effective, and affordable alternatives to existing brand biologics that meet the same standards set by the US Food and Drug Administration (FDA). They have lower costs and are believed to decrease the burdens of hospitalization and ambulatory care. Coherus Biosciences develops biologic medicines such as immunology therapies, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates, ophthalmology biosimilar candidates, and oncology biosimilar candidates.
Geographically, the group has a business presence in the United States and other countries. The company has a strategic collaboration with Daiichi Sankyo.
President, Chief Executive Officer & Chairman
Thomas Fitzpatrick JD
Chief Legal Officer
Chief Scientific Officer